Lumos Pharma Statistics
Total Valuation
Lumos Pharma has a market cap or net worth of $21.00 million. The enterprise value is -$14.49 million.
| Market Cap | 21.00M |
| Enterprise Value | -14.49M |
Important Dates
The next estimated earnings date is Wednesday, May 1, 2024, after market close.
| Earnings Date | May 1, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Lumos Pharma has 8.11 million shares outstanding. The number of shares has decreased by -2.73% in one year.
| Shares Outstanding | 8.11M |
| Shares Change (YoY) | -2.73% |
| Shares Change (QoQ) | +1.46% |
| Owned by Insiders (%) | 34.83% |
| Owned by Institutions (%) | 29.30% |
| Float | 5.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.24 |
| Forward PS | 2.28 |
| PB Ratio | 0.77 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.70, with a Debt / Equity ratio of 0.02.
| Current Ratio | 5.70 |
| Quick Ratio | 5.16 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -85.60% and return on invested capital (ROIC) is -131.28%.
| Return on Equity (ROE) | -85.60% |
| Return on Assets (ROA) | -65.30% |
| Return on Capital (ROIC) | -131.28% |
| Revenue Per Employee | $62,152 |
| Profits Per Employee | -$1.03M |
| Employee Count | 33 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -29,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.64% in the last 52 weeks. The beta is 0.35, so Lumos Pharma's price volatility has been lower than the market average.
| Beta (1Y) | 0.35 |
| 52-Week Price Change | -15.64% |
| 50-Day Moving Average | 2.87 |
| 200-Day Moving Average | 3.13 |
| Relative Strength Index (RSI) | 41.17 |
| Average Volume (30 Days) | 19,825 |
Short Selling Information
The latest short interest is 287,463, so 3.55% of the outstanding shares have been sold short.
| Short Interest | 287,463 |
| Short Previous Month | 293,569 |
| Short % of Shares Out | 3.55% |
| Short % of Float | 5.42% |
| Short Ratio (days to cover) | 11.21 |
Income Statement
In the last 12 months, Lumos Pharma had revenue of $2.05 million and -$34.03 million in losses. Loss per share was -$4.18.
| Revenue | 2.05M |
| Gross Profit | 2.05M |
| Operating Income | -36.61M |
| Pretax Income | -34.06M |
| Net Income | -34.03M |
| EBITDA | -34.02M |
| EBIT | -34.06M |
| Loss Per Share | -$4.18 |
Balance Sheet
The company has $36.08 million in cash and $585,000 in debt, giving a net cash position of $35.49 million or $4.38 per share.
| Cash & Cash Equivalents | 36.08M |
| Total Debt | 585,000 |
| Net Cash | 35.49M |
| Net Cash Per Share | $4.38 |
| Equity / Book Value | 27.31M |
| Book Value Per Share | 3.37 |
| Working Capital | 33.01M |
Cash Flow
| Operating Cash Flow | -31.10M |
| Capital Expenditures | n/a |
| Free Cash Flow | -31.10M |
| FCF Per Share | -$3.82 |
Margins
Gross margin is 100.00%, with operating and profit margins of -1,785.18% and -1,659.39%.
| Gross Margin | 100.00% |
| Operating Margin | -1,785.18% |
| Pretax Margin | -1,660.80% |
| Profit Margin | -1,659.39% |
| EBITDA Margin | -1,658.65% |
| EBIT Margin | -1,660.80% |
| FCF Margin | -1,516.09% |
Dividends & Yields
Lumos Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.73% |
| Shareholder Yield | 2.73% |
| Earnings Yield | -162.09% |
| FCF Yield | -148.09% |
Analyst Forecast
The average price target for Lumos Pharma is $18.00, which is 594.98% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $18.00 |
| Price Target Difference | 594.98% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 175.52% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on March 19, 2020. It was a reverse split with a ratio of 1:9.
| Last Split Date | Mar 19, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:9 |
Scores
Lumos Pharma has an Altman Z-Score of -6.36 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.36 |
| Piotroski F-Score | 3 |